Medical/Pharmaceuticals
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
Data showed an excellent safety profile with no adverse events among the five subjects treated. Company continues to explore doses in the ongoing Phase II dose escalation study GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock ...
2022-08-29 15:59
4241
Össur Acquires Naked Prosthetics
HÄMEENLINNA, Finland, Aug. 29, 2022 /PRNewswire/ -- Össur has acquired Naked Prosthetics, a leading provider of durable, custom and functional finger prostheses for finger and partial hand amputees, with effect from26 August 2022 . The mechanical devices are individually designed to mimic the natu...
2022-08-29 15:32
2779
Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress
* The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently. * Cash reserve was nearly RMB 1.5 billion, which provided support to sustainable innovation and commercialization. * The novel adjuvants vaccine will create a strong growth engine. TAIZHOU, China, ...
2022-08-29 13:08
5213
Fosun International Listed in Forbes 2022 China ESG 50
HONG KONG, Aug. 29, 2022 /PRNewswire/ -- Forbes China recently released its "2022 China ESG 50" list. Fosun International has been included on the list for its outstanding ESG performance and its active contribution to the fight against the COVID-19 pandemic.Forbes China pointed out that ESG is s...
2022-08-29 12:52
5009
Porton Advanced and Royaltech Announce Strategic Collaboration to Accelerate the Development of Bacterial Drugs and mRNA Drugs
SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions. (hereinafter referred to as Porton Advanced) announced a strategic cooperation with Suzhou Royaltech Med Co., Ltd. (hereinafter referred to as Suzhou Royaltech).This strategic collaboration will further in...
2022-08-29 12:23
2814
Sanyou Biopharmaceuticals and KangaBio established strategic collaboration to accelerate antibody drug development and innovation
SHANGHAI, Aug. 27, 2022 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals ( Shanghai) Co., Ltd. (Sanyou) and Shanghai KangaBio Co., Ltd. (KangaBio) have reached an antibody drug licensing agreement, regarding a proprietary monoclonal antibody drug developed by Sanyou, which grants KangaBio an e...
2022-08-28 08:00
4633
Infinitus co-organizes "Traditional Chinese Medicine Cultural Communication ▪ We are in Action" event
CAE academician Yu Mengsun and Master of traditional Chinese medicine Zhou Daihan visit Infinitus GUANGZHOU, China, Aug. 27, 2022 /PRNewswire/ -- On August 21, 2022, the Guangdong leg of the "Traditional Chinese Medicine Cultural Communication · We are in Action" event, jointly organized by the...
2022-08-27 09:15
8416
ProSomnus® Sleep Technologies Announces Signing of Definitive Agreements for $30 Million of Convertible Notes
Financing will support Company's pending business combination and fund strategic growth initiatives SAN FRANCISCO, Aug. 26, 2022 /PRNewswire/ -- ProSomnus Sleep Technologies ("ProSomnus"), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today a...
2022-08-27 04:30
8802
Ascentage Pharma Announces 2022 Interim Results
SUZHOU, China and ROCKVILLE, Md. , Aug. 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results. During the reporting p...
2022-08-27 00:47
15824
Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization
BEIJING, Aug. 26, 2022 /PRNewswire/ -- On August 26, 2022 (Beijing time), Ocumension Therapeutics (1477.HK) released its 2022 interim report. The Company's overall performance remained remarkable despite the fact that the pandemic caused considerable trouble in commercializing its ophthalmic prod...
2022-08-26 22:09
13196
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead™ RNAi delivery platform f...
2022-08-26 21:54
11280
First approval of Cadonilimab (PD-1/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal
HONG KONG, Aug. 26, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring onCadonilimab, a first-in-cla...
2022-08-26 20:00
3876
Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both intravenous and subcutaneous administration Poster presentations demonstrate synergistic effects of s...
2022-08-26 19:30
3677
VISTA Eye Specialists joins Qualitas Health Family to further strengthen Qualitas' healthcare foothold in Asia Pacific
PETALING JAYA, Malaysia, Aug. 26, 2022 /PRNewswire/ -- VISTA Eye Specialists (VISTA) officially joins the Qualitas Health integrated network of clinics in Asia in a collaboration borne out of the attraction towards values that they share - to provide the Malaysians with access to quality healthcar...
2022-08-26 08:00
4822
Everest Medicines Announces the Departure of CEO, Kerry Blanchard
SHANGHAI, Aug. 26, 2022 /PRNewswire/ -- Everest Medicines
2022-08-26 07:30
5788
Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan
* Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan Food and Drug Administration * Lunit's latest commercial approval to accelerate expansion in the Taiwanese market SEOUL, South Korea, Aug. 25, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a leading...
2022-08-25 23:13
4837
Doctors at Manipal Hospitals, Dwarka give new lease of life to a 30-day-old newborn suffering from brain tumor
NEW DELHI and KHARTOUM, Sudan, Aug. 25, 2022 /PRNewswire/ -- Doctors at Manipal Hospitals,Delhi successfully saved the life of a 30-day-old newborn baby with a brain tumor. The baby was presented at the hospital in an emergency with a complaint of seizures and unconsciousness. Upon further diagno...
2022-08-25 21:00
4794
Innovent Announced 2022 Interim Results and Business Updates
* Leading the Way in Developing a More Sustainable Business Model for Innovative Biopharmaceutical Companies * Commercial Model and Platform Upgraded to Stage 2.0 * A Robust Pipeline of 34 Valuable Assets Supporting Continuously Growth Momentum ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2022...
2022-08-25 20:06
7196
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELBOURNE, Australia and SAN FRANCISCO, Aug. 25, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing diseas...
2022-08-25 19:25
3606
Tigermed Reports 2022 Interim Result with Strong Financial Growth
HANGZHOU, China, Aug. 25, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its interi...
2022-08-25 19:05
4889
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
44426
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
34516
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
19919
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
17712
